Skip to main content
TP

TIRmed Pharma

TIRmed Pharma is developing TIR-01, a topical cream that modulates immune responses to alleviate mild to moderate eczema symptoms by reducing itch and promoting tissue regeneration. This non-invasive treatment offers a sustained effect without complete immune suppression, addressing the need for effective alternatives to steroid-based therapies.

Founded 20186200+ followers
Updated 20 months ago

Funding

$4.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

SV
Funding rounds are not available yet.

Founders

Product

Problem

Mild to moderate eczema symptoms, characterized by itch and tissue damage, require treatments that avoid complete immune suppression and provide sustained relief. Current steroid-based therapies can have undesirable side effects, creating a need for effective, non-steroidal alternatives.

Solution

TIRmed Pharma is developing TIR-01, a topical cream designed to modulate immune responses and alleviate mild to moderate eczema symptoms. The water-based cream is applied topically and works by temporarily inhibiting mast cell degranulation and dendritic cell activation, while also stimulating IL-10 production. This approach aims to reduce itch and promote tissue regeneration without fully suppressing the immune system, leading to sustained symptom inhibition even beyond the treatment period. The cream targets the affected area to dampen T-helper responses and support the regeneration of damaged tissue, breaking the cycle of itching and worsening atopic dermatitis symptoms.

Target Audience

The primary target audience includes individuals with mild to moderate eczema, particularly children and young adults seeking effective, non-steroidal topical treatments.

Features

  • Topical, water-based cream formulation for easy, self-administration by patients
  • Immunomodulatory action that temporarily inhibits mast cell degranulation and dendritic cell activation
  • Stimulation of IL-10 production to promote immune regulation
  • Targeted T-helper response dampening to reduce itch sensation
  • Promotion of tissue regeneration to reverse eczema-related damage
  • Non-steroidal mechanism of action to avoid side effects associated with steroid-based treatments
This profile is AI-generated and may contain inaccuracies.